Cambridge spin-out XO1, which is developing anticoagulants that could have a sizeable impact on preventing heart attacks and strokes, has received $11m from Index Ventures. The life science investor was the sole participant in the $11m round, made through Index’s $200m Life Sciences fund launched last year, and represents the company’s largest investment in a…
Index pumps $11m into Cambridge spin-out
Jun 19, 2013 •
LEADERSHIP SOCIETYInforming, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
More featured content
Resistance is futile: seven superconductor companies that want to change the world
From healthcare to fusion to quantum computing to space, superconductors have the potential to revolutionise the world. And the technology is finally ready to commercialise.
UK universities urged to lower spinout stakes
A new report recommends stakes of less than 25% but fails to address the issue of access to early-stage capital.
Feb 7, 2024
Mar 14, 2024
Monterey, CA (USA)
Jun 26, 2024